KBY Biotech Indexv0.0.34
Search
← Pipeline|AIP-7637

AIP-7637

NDA/BLA
By Adcock Ingram
Source: Trial-derived·Trials: 2
Modality
Degrader
MOA
SHP2i
Target
GPRC5D
Pathway
Checkpoint
IPFFabryObesity
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
~Oct 2018
→ ~Jan 2020
Phase 3
~Apr 2020
→ ~Jul 2021
NDA/BLA
Oct 2021
→ Sep 2031
NDA/BLACurrent
NCT07234158
2,712 pts·Fabry
2021-10→2026-12·Recruiting
NCT04278365
2,574 pts·Obesity
2024-04→2031-09·Terminated
5,286 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-048mo awayPh3 Readout· Fabry
2031-09-185.5y awayPh3 Readout· Obesity
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-12-04 · 8mo away
Fabry
Ph3 Readout
2031-09-18 · 5.5y away
Obesity
RecruitingTerminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT07234158NDA/BLAFabryRecruiting2712FEV1
NCT04278365NDA/BLAObesityTerminated2574HAM-D
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2191PfizerNDA/BLAGLP-1RSHP2i
PexatenlimabNovartisPhase 1/2GPRC5DKIF18Ai
RibotuximabMerck & CoPhase 2GPRC5DEZH2i
BMY-9931Bristol-Myers SquibbPhase 1GPRC5DFXIai
DoxacageneSanofiApprovedPSMASHP2i
NVO-7877Novo NordiskPreclinicalGPRC5DFXIai
AMG-9654AmgenPhase 2GPRC5DDLL3 ADC
GIL-9227Gilead SciencesPhase 2/3GPRC5DCDK2i
VRT-1576Vertex PharmaPhase 2/3RETSHP2i
SovafutibatinibModernaApprovedFcRnSHP2i